Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 799 results for "maa exchange"

SEBI bars Gammon Infra's ex-CMD in insider trading

Market regulator Securities and Exchange Board of India (SEBI) on Thursday barred Gammon Infrastructure Projects' former CMD Abhijit Rajan from securities market after prima-facie finding him to have violated insider trading regulations in the ... VC Circle, 1 week ago
Scottrade

Publicis Groupe's H1 profit drops down 17 per cent, exchange rates impact numbers

MUMBAI: With the slowdown of global economic activity since the start of the year and economic uncertainties prevailing in several regions of the world, Publicis Groupe has announced that its second-quarter performance was well below that of the ...
 Indian Television3 days ago Publicis Groupe: First Half-Year 2014 Results  Morningstar.com4 days ago
[x]  
Scottrade

Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections

- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that it submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of isavuconazole for the treatment of invasive aspergillosis and ...
 Vision Monday1 week ago Basilea reicht europäischen Zulassungsantrag für Isavuconazol zur Behandlung invasiver Schimmelpilzinfektionen ein  Quoteline1 week ago Basilea Pharmaceutica Isavuconazole European Marketing Authorization Application For The Treatment Of Invasive Mold Infections  BioSpace1 week ago BASILEA PHARMACEUTICA AG : submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections  4 Traders1 week ago
[x]  

European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia

CHESHIRE, Conn. -- (BUSINESS WIRE) -- (NASDAQ:ALXN) today announced that the Marketing Authorization Application (MAA) for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia ...
 Freshnews.com2 days ago Alexion Reports Second Quarter 2014 Results  CNBC2 days ago ALEXION PHARMACEUTICALS : Reports Second Quarter 2014 Results  4 Traders2 days ago ALEXION PHARMACEUTICALS : European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia  4 Traders2 days ago
[x]  

GEM Notice

RNS Number : 5303M Irish Stock Exchange 16 July 2014 REPORT OF THE BOARD OF THE IRISH STOCK EXCHANGE ADMISSION NOTICE Irish Stock Exchange 28 Anglesea Street Dublin 2 16th July 2014 The ...
 TrustNet1 week ago
Yahoo! News

Mali Govt., Rebels Swap Prisoners ahead of Peace Talks

:26 Tuareg rebels and the Malian government on Tuesday exchanged dozens of prisoners in a goodwill gesture on the eve of peace talks opening in Algiers, an Agence France Presse correspondent witnessed. Forty-five Malian soldiers and police ...
 Naharnet1 week ago Mali govt, rebels swap prisoners before peace talks  Channel Africa1 week ago Mali govt, rebels swap prisoners ahead of peace talks  Modern Ghana1 week ago

InfyTalk: Building tomorrow's health and human services with MaaS

The discussion about Obamacare heats up [Source: http://www.youtube.com/watch-v=Xxz7foLoLrU] States face a balancing act. They need to comply with regulatory mandates to expand health insurance coverage under the Affordable Care Act (ACA); an act ...
 Infosys BPO15 hours ago

Europese CHMP geeft positief advies over Gileads Zydelig® (idelalisib) voor de behandeling van chronische lymfatische leukemie en folliculair lymfoom

FOSTER CITY, Californië (VS)--( BUSINESS WIRE )--Gilead Sciences, Inc. (NASDAQ: GILD) kondigde vandaag aan dat de commissie voor geneesmiddelen voor menselijk gebruik (Committee for Medicinal Products for Human Use, CHMP), de ...
 Business Wire15 hours ago European CHMP Adopts Positive Opinion for Gilead's Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma  Tamar Securities1 day ago Gilead Sciences : European CHMP Adopts Positive Opinion for Gilead's Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma  4 Traders1 day ago
[x]  
EuroInvestor

Kidney Dialysis Drug Phase 3 Data Boost Keryx Biopharmaceuticals's Hopes For U.S. Approval

Zerenex (Ferric Citrate) Long-Term Phase 3 Study Results Published In The Journal Of The American Society Of Nephrology NEW YORK, July 24, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ...
 BioSpace18 hours ago Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology  EuroInvestor1 day ago DGAP-News: Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology (english)  Pharmacy Choice1 day ago Zerenex (ferric citrate) long-term Phase 3 study results published in JASN  EurekAlert!1 day ago
[x]  

ALEXION PHARMACEUTICALS INC - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

A (Edgar Glimpses Via Acquire Media NewsEdge) Note Regarding Forward-Looking Statements This quarterly report on Form 10-Q contains forward-looking statements that have been made pursuant to the provisions of the Private Securities Litigation Reform ...
 TMC Net19 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less